Clinical Programs

Myeloid Therapeutics is a clinical stage company with multiple programs including Primed and ATAK Monocytes that address high unmet need cancers.

Primed Monocyte Program

Our primed monocytes are engineered myeloid cells  that stimulate an immune response to cancer.

 

MT-201

Glioblastoma

DISCOVERY

LEAD OPTIMIZATION

IND-ENABLING

PHASE 1

We are advancing our glioblastoma program to clinical stage in partnership with Duke University after showing potent anti-tumor activity in animal cancer models.

Cell Therapy Programs

Using a harmonized, one-day manufacturing process, we are moving into the clinic with our ATAK  monocytes.  These myeloid cells are engineered with a novel CAR design that triggers tumor-specific phagocytosis and secretion of pro-inflammatory cytokines, resulting in a hot tumor microenvironment and causing tumor cell death.  In addition, ATAK monocytes sustain the ability to cross-present antigens, generating a durable anti-tumor response by cytotoxic T cells.

 

MT-101

T Cell Lymphoma

DISCOVERY

LEAD OPTIMIZATION

IND-ENABLING

PHASE 1

MT-101 is being developed for the treatment of relapsed and refractory CD5-expressing T cell lymphomas. Refractory PTCL is a lethal disease with limited treatment options, that until now has not benefited from innovations in cell therapy.

In vitro and in vivo studies show MT-101 demonstrated meaningful anti-tumor activity. Treatment in these models has been associated with potent phagocytosis responses, the production of inflammatory mediators and delays in tumor progression.
 

MT-102

HER2+ Solid Tumors 

DISCOVERY

LEAD OPTIMIZATION

IND-ENABLING

PHASE 1

MT-102 is being developed for individuals with HER2 expressing cancers. In vivo studies show MT-102 has eradicated HER2+ tumors.

MT-103

TROP2 Solid Tumors

DISCOVERY

LEAD OPTIMIZATION

IND-ENABLING

PHASE 1

MT-103 targets tumors with TROP2 antigen.

 
 

© 2020,   Myeloid Therapeutics.  All rights reserved.                 Privacy Policy     |     Terms of Use     |      Cookie Policy

  • LinkedIn
  • Instagram
  • Twitter

300 Technology Square, Suite 203      |      Cambridge, Massachusetts 02139